SG10201907677QA - Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases. - Google Patents
Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases.Info
- Publication number
- SG10201907677QA SG10201907677QA SG10201907677QA SG10201907677QA SG10201907677QA SG 10201907677Q A SG10201907677Q A SG 10201907677QA SG 10201907677Q A SG10201907677Q A SG 10201907677QA SG 10201907677Q A SG10201907677Q A SG 10201907677QA SG 10201907677Q A SG10201907677Q A SG 10201907677QA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations
- prevention
- treatment
- peripheral neuropathy
- associated diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201907677QA SG10201907677QA (en) | 2019-08-20 | 2019-08-20 | Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases. |
| EP20854153.2A EP4017496A4 (en) | 2019-08-20 | 2020-07-14 | Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases |
| KR1020227008958A KR102852882B1 (en) | 2019-08-20 | 2020-07-14 | Formulations for use in the prevention and/or treatment of peripheral neuropathy and related diseases |
| CA3151797A CA3151797A1 (en) | 2019-08-20 | 2020-07-14 | Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases. |
| CN202080071678.2A CN114555091B (en) | 2019-08-20 | 2020-07-14 | Formulation for preventing and/or treating peripheral neuropathy and related diseases |
| PCT/SG2020/050406 WO2021034267A1 (en) | 2019-08-20 | 2020-07-14 | Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases. |
| US17/636,917 US20220387440A1 (en) | 2019-08-20 | 2020-07-14 | Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases |
| JP2022510956A JP2022545223A (en) | 2019-08-20 | 2020-07-14 | Preparations for the prevention and/or treatment of peripheral neuropathy and related diseases |
| TW109124632A TWI887256B (en) | 2019-08-20 | 2020-07-21 | Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201907677QA SG10201907677QA (en) | 2019-08-20 | 2019-08-20 | Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201907677QA true SG10201907677QA (en) | 2021-03-30 |
Family
ID=74660762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201907677QA SG10201907677QA (en) | 2019-08-20 | 2019-08-20 | Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220387440A1 (en) |
| EP (1) | EP4017496A4 (en) |
| JP (1) | JP2022545223A (en) |
| KR (1) | KR102852882B1 (en) |
| CN (1) | CN114555091B (en) |
| CA (1) | CA3151797A1 (en) |
| SG (1) | SG10201907677QA (en) |
| TW (1) | TWI887256B (en) |
| WO (1) | WO2021034267A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024061971A1 (en) * | 2022-09-21 | 2024-03-28 | Wista Laboratories Ltd. | Novel formulations and vehicles |
| WO2025091016A1 (en) * | 2023-10-26 | 2025-05-01 | Indiana University Research And Technology Corporation | Compositions comprising p75ntr inhibitors and recombinant nerve growth factor and methods for the treatment of corneal diseases and disorders using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100816670B1 (en) * | 2006-08-18 | 2008-03-27 | 국방과학연구소 | Use of methylene blue to treat retinal damage and to protect the retina |
| CA2934578A1 (en) * | 2013-12-20 | 2015-06-25 | University Of Manitoba | Compositions comprising muscarinic m1 receptor antagonists for treatment of non-diabetic peripheral neuropathies |
| US9867787B2 (en) * | 2015-04-27 | 2018-01-16 | The University Of Hong Kong | Hypromellose-graft-chitosan and methods thereof for sustained drug delivery |
| WO2017132639A1 (en) * | 2016-01-30 | 2017-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated anchoring of therapeutic factors to tissues |
| EP3654950A4 (en) * | 2017-07-17 | 2021-04-21 | Wolfcreek Biotech Pte Ltd | Microparticle formulations for delivery of active agents |
-
2019
- 2019-08-20 SG SG10201907677QA patent/SG10201907677QA/en unknown
-
2020
- 2020-07-14 KR KR1020227008958A patent/KR102852882B1/en active Active
- 2020-07-14 CA CA3151797A patent/CA3151797A1/en active Pending
- 2020-07-14 WO PCT/SG2020/050406 patent/WO2021034267A1/en not_active Ceased
- 2020-07-14 CN CN202080071678.2A patent/CN114555091B/en active Active
- 2020-07-14 JP JP2022510956A patent/JP2022545223A/en active Pending
- 2020-07-14 US US17/636,917 patent/US20220387440A1/en active Pending
- 2020-07-14 EP EP20854153.2A patent/EP4017496A4/en active Pending
- 2020-07-21 TW TW109124632A patent/TWI887256B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114555091B (en) | 2024-08-23 |
| KR102852882B1 (en) | 2025-09-02 |
| US20220387440A1 (en) | 2022-12-08 |
| KR20220066060A (en) | 2022-05-23 |
| JP2022545223A (en) | 2022-10-26 |
| WO2021034267A1 (en) | 2021-02-25 |
| EP4017496A1 (en) | 2022-06-29 |
| TW202108144A (en) | 2021-03-01 |
| CA3151797A1 (en) | 2021-02-25 |
| EP4017496A4 (en) | 2023-08-23 |
| TWI887256B (en) | 2025-06-21 |
| CN114555091A (en) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282629A (en) | Formulation based on medicinal plant, part or extract of the it, use of the formulation and product comprising that formulation | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| PL3577135T3 (en) | A pharmaceutical composition for use in the treatment or prevention of c5-related diseases | |
| GB201915522D0 (en) | Use of cannabidiol preparations in the treatment of absence epilepsy | |
| IL289167A (en) | 2h-indazole derivatives and their use in the treatment of disease | |
| IL274578A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| PL3829628T3 (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease | |
| PT3810128T (en) | Compositions for treating and/or preventing protein-aggregation diseases | |
| MX2020001632A (en) | Compositions comprising bacterial strains. | |
| IL289758B1 (en) | Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries | |
| WO2019175260A3 (en) | Modified oligonucleotides for use in treatment of tauopathies | |
| IL272495A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| SG10201907677QA (en) | Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases. | |
| PL3937948T3 (en) | Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases | |
| IL268131A (en) | A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease | |
| PL3829553T3 (en) | Composition for use in the prevention and/or treatment of the genitourinary mucosa | |
| PL3713590T3 (en) | Human beta 2 defensin for use in the prevention and treatment of graft-versus-host-disease | |
| EP3646872A4 (en) | Agent for preventing and/or treating alzheimer's disease | |
| IL284298A (en) | Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases | |
| IL282718A (en) | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity | |
| PL3813843T3 (en) | Composition for use in the prevention and/or treatment of osteoarticular diseases | |
| IT201700109607A1 (en) | Composition for use in the prevention and / or treatment of glaucoma. | |
| GB2603379B (en) | Avocatin B for the treatment of diseases and conditions | |
| HK40062286A (en) | Barn dust extract for the prevention and treatment of diseases | |
| PL4081507T3 (en) | Chemical compounds targeting the eye and use thereof in the treatment of eye diseases |